R J van de Stadt
Overview
Explore the profile of R J van de Stadt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Eijk I, de Vries M, Levels J, Peters M, Huizer E, Dijkmans B, et al.
Arthritis Rheum
. 2009 May;
60(5):1324-30.
PMID: 19404933
Objective: Cardiovascular mortality is increased in ankylosing spondylitis (AS), and inflammation plays an important role. Inflammation deteriorates the lipid profile and alters high-density lipoprotein cholesterol (HDL-c) composition, reflected by increased...
2.
Bos W, Wolbink G, Boers M, Tijhuis G, de Vries N, van der Horst-Bruinsma I, et al.
Ann Rheum Dis
. 2009 Apr;
69(3):490-4.
PMID: 19363023
Background: Anti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis. Objective: To investigate the effect of the presence and levels of ACPA on arthritis development in patients...
3.
Bos W, Dijkmans B, Boers M, van de Stadt R, van Schaardenburg D
Ann Rheum Dis
. 2009 Apr;
69(3):571-4.
PMID: 19363022
Background: Rheumatoid arthritis is characterised by antibodies to citrullinated proteins (ACPA) and rheumatoid factor (RF) in the preclinical phase. Objective: To determine whether an intervention aimed at decreasing autoantibody levels...
4.
Steen K, Lems W, Visman I, de Koning M, van de Stadt R, Twisk J, et al.
Clin Exp Rheumatol
. 2009 Mar;
27(1):170.
PMID: 19327252
No abstract available.
5.
Levitus M, Pelliccia A, van de Stadt R, Voskuyl A, Bouman A
Clin Rheumatol
. 2009 Jan;
28(4):469-74.
PMID: 19165556
Treatment of rheumatoid arthritis (RA) is monitored with the disease activity score (DAS28), for which the erythrocyte sedimentation rate (ESR) is needed. Apart from the original gold standard method, other...
6.
van Schaardenburg D, Bos W, Ursum J, van de Stadt R, van Denderen J, Dijkmans B
Ned Tijdschr Geneeskd
. 2008 Jun;
152(21):1244.
PMID: 18578456
No abstract available.
7.
Bos W, Bartelds G, Vis M, van der Horst A, Wolbink G, van de Stadt R, et al.
Ann Rheum Dis
. 2008 May;
68(4):558-63.
PMID: 18445623
Objective: To investigate the dynamics of IgG1 and IgG4 anti-citrullinated protein antibody (ACPA) subclasses during anti-tumour necrosis factor (TNF) treatment in patients with rheumatoid arthritis (RA). Methods: IgG, IgG1 and...
8.
Bos W, Ursum J, de Vries N, Bartelds G, Wolbink G, Nurmohamed M, et al.
Ann Rheum Dis
. 2008 Apr;
67(9):1347-50.
PMID: 18388157
Objectives: Patients presenting with both arthralgia and antibodies to cyclic citrullinated peptide (anti-CCP) have an increased risk of developing rheumatoid arthritis (RA). To further characterise this patient group and shed...
9.
Peters M, Vis M, van Halm V, Wolbink G, Voskuyl A, Lems W, et al.
Ann Rheum Dis
. 2007 Feb;
66(7):958-61.
PMID: 17314120
Objective: To evaluate the effects of infliximab and corticosteroid treatment on the lipid profile in patients with active rheumatoid arthritis (RA). Methods: Infliximab infusions were given at weeks 0, 2,...
10.
van Halm V, Nielen M, Nurmohamed M, van Schaardenburg D, Reesink H, Voskuyl A, et al.
Ann Rheum Dis
. 2006 Jun;
66(2):184-8.
PMID: 16760255
Background: Rheumatoid arthritis is characterised by inflammation and an increased cardiovascular risk. It was recently shown that active early rheumatoid arthritis is associated with dyslipidaemia, which may partially explain the...